Skip to main content

Table 4 Comparison of breast cancer-specific survival (BCSS) and overall survival (OS) between matched patients with chemotherapy and no-chemotherapy in specific stage

From: The impact of chemotherapy and survival prediction by machine learning in early Elderly Triple Negative Breast Cancer (eTNBC): a population based study from the SEER database

Stage

BCSS

OS

Events No

HRs (95%CI)

P a

Events No

HRs (95%CI)

P a

Stage I ( n  = 1,312)

53

 

0.932

103

 

0.111

 Chemotherapy

 

1.024(0.595–1.764)

  

0.723(0.485–1.078)*

 

 No-Chemotherapy

 

Reference

  

Reference

 

Stage II ( n  = 985)

164

 

0.001

247

 

 < 0.001

 Chemotherapy

 

0.564(0.408–0.779)

  

0.522(0.400–0.682)*

 

 No-Chemotherapy

 

Reference

  

Reference

 

Stage III ( n  = 363)

142

 

0.001

192

 

 < 0.001

 Chemotherapy

 

0.549(0.386–0.781)

  

0.537(0.395–0.728)*

 

 No-Chemotherapy

 

Reference

  

Reference

 

Stage I-III ( n  = 2,660)

359

 

 < 0.001

542

 

 < 0.001

 Chemotherapy

 

0.612(0.493–0.759)*

  

0.549(0.459–0.655)*

 

 No-Chemotherapy

 

Reference

  

Reference

 
  1. Abbreviation: HR Hazard ratio, CI Confidence interval, BCSS Breast cancer-specific survival, OS Overall survival, Events No Number of events
  2. aP value was adjusted by a multivariate Cox proportional hazard regression model or a time-dependent covariate analysis. Bold type indicates significance
  3. bThe groups using time-dependent covariate analysis were specifically marked with asterisks(*)
Back to article page

BMC Geriatrics

ISSN: 1471-2318

Contact us